Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Liposomal iRInotecan, Carboplatin or oXaliplatin in the First Line Treatment of Esophagogastric Cancer: a Randomized Phase 2 Study

NCT03764553 is registered in ClinicalTrials.gov with Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) as lead sponsor.

NCT NCT03764553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03764553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Liposomal iRInotecan, Carboplatin or oXaliplatin in the First Line Treatment of Esophagogastric Cancer: a Randomized Phase 2 Study
Lead sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 1, 2019
Completion date
December 1, 2026
Enrollment
320 (estimated)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer